






































































































































































































































ith nasal polyps (CRSw
NP) is a chronic inflam
m
atory disease of the nasal and 
paranasal sinuses associated w
ith high sym
ptom




inantly displays a type 2 inflam
m
atory signature w
ith interleukin (IL)-4, IL-5, and  
IL-13 as prom





ents options for CRSw
NP, lim
ited to the chronic use of intranasal corticosteroids (INCS), 
short courses of system




orsen, and surgery w
hen m
edication 











3,4  that blocks the shared receptor 






ab is approved in the USA for patients aged ≥ 12 years w
ith m
oderate-to-severe eosinophilic 
or oral corticosteroid-dependent asthm
a
6–8 and for the treatm
ent of adults w
ith inadequately controlled 
m
oderate-to-severe atopic derm
atitis in several countries
9–11
• 
In a phase 2a proof-of-concept study (ClinicalTrials.gov Identifier: NCT01920893), dupilum
ab on a 
background of m
om
etasone furoate nasal spray (M
FNS) significantly im
proved endoscopic, radiographic, 
clinical, and patient-reported outcom
es in patients w
ith CRSw
NP refractory to INCS
12
• 
The phase 3 study SINUS-52 (NCT02898454) w
as conducted to further investigate dupilum
ab  
efficacy and safety in treating patients w
ith severe CRSw










To evaluate the efficacy and safety of dupilum
ab com
pared w
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m














ith severe uncontrolled CRSw
NP, dupilum
ab as add-on to M
FNS significantly 
im
proved all disease com









ents in all outcom
e m
easures w
ere noted early in treatm
ent (at the first assessm
ent 
tim
e point) and continued to im










proved lung function and asthm





a, a difficult-to-treat patient population 
• 
Overall, the 300 m
g q2w
 regim
en had better sustained im
provem
ents in the objective m
easures 
of NPS and LM
K-CT scan score and few
er breakthrough TEAEs of w
orsening of nasal polyps, 
asthm
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ab is in clinical developm
ent for treatm
ent of chronic rhinosinusitis w
ith nasal polyps and 
currently has no m





















































NP, nasal polyp; q2w
, every 2 w
eeks; q4w
, every 4 w
eeks; R, random
ization; SC, subcutaneous. 
Figure 1. S



















The design of this m
ultinational, m
ulticenter, random
ized, double-blind, phase 3, placebo-controlled, 
parallel-group study is show
n in Figure 1
• 








































ed at the investigator’s discretion
• 
The patient population w
as stratified for com
orbid asthm
a/AERD (aspirin and nonsteroidal anti-
inflam
m




Adult patients aged ≥ 18 years w
ho have undergone prior treatm
ent w
ith or have contraindication/
intolerance to SCS in the past 2 years, or have had prior surgery for NPs, w
ith bilateral endoscopic nasal 
polyp score (NPS) ≥ 5 (out of 8), w
ith ≥ 2 for each nostril
• 
2 or m


























ithin 130 days before screening
• 
Sinus surgery (including polypectom
y) w
ithin 6 m
onths before screening or sinonasal surgery changing 
the lateral w
all structure of the nose, m




ith forced expiratory volum
e in 1 second (FEV
1 ) ≤ 50%










 baseline in endoscopic NPS at W
eek 24 for dupilum
ab (pooled Arm
 A+B) vs placebo
 –
Change from
 baseline in patient-reported nasal congestion (NC) score at W
eek 24 for dupilum
ab 
(pooled Arm










K-CT) score for dupilum
ab (pooled Arm
 A+




 baseline in patient-reported total sym
ptom
 score (TSS), University of Pennsylvania Sm
ell 
Identification Test (UPSIT) score, daily loss-of-sm
ell score, and 22-item
 Sino-Nasal Outcom
e Test 
(SNOT-22) score at W
eek 24 for dupilum
ab (pooled Arm
 A+B) vs placebo 
 –
Change from
 baseline in endoscopic NPS, NC score, and SNOT-22 score at W
eek 52 for dupilum
ab 
(Arm
 A) vs placebo
Table 1. Baseline dem
























































































































































aHigher scores indicate greater disease severity except for UPSIT, w
here higher scores indicate low
er disease severity.  




































TEAEs occurring in ≥ 5%
















































aDefined as events occurring from
 the first adm
inistration of study m
edication to the end of the post-treatm
ent period by M
edical Dictionary for 






































      from
 baseline at W






 vs placebo significantly reduced N
C
 score 
      from
 baseline at W
eeks 24 and 52
W
eek 24



























































inal significance at W
eek 4,




































inal significance at W
eek 4,



































 and 300 m
g q2w
–q4w










***P < 0.0001 for dupilum
ab vs placebo. P < 0.0001 for dupilum
ab 300 m
g q2w
 and 300 m
g q2w
–q4w
 vs placebo at all tim
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ab vs placebo increased U
P
S
IT score at W
eek 4,
      continued to W
eek 52
























ab vs placebo reduced daily loss-of-sm
ell score at W
eek 4,











































ab vs placebo reduced S
N
O
T-22 total score at W
eek 4,

































































































































































 and 300 m
g q2w
–q4w
) vs placebo im
proved clinical and patient-reported outcom
es in the ITT population.
***P < 0.0001 for dupilum
ab vs placebo. P < 0.0001 for dupilum
ab 300 m
g q2w
 and 300 m
g q2w
–q4w
 vs placebo at all tim
e points. For SNOT-22 score, differences > 8.9 are considered clinically relevant.
• 
The follow
ing additional endpoints w
ere also evaluated:
 –
Proportion of patients during study treatm
ent w






 baseline to W
eek 24 in lung function (FEV
1  [L]), and 
asthm
a control, m
easured by the 6-item
 Asthm










Each of the 2 co-prim
ary efficacy endpoints and the key secondary endpoints w
ere prospectively 
defined and m
ultiplicity adjusted, and w
ere analyzed using a hybrid m










s for efficacy analyses
 –
For analyses of change from
 baseline to W
eek 24, Arm









) as both groups w
ere receiving 300 m
g q2w












 A (300 m
g q2w
 for 52 w
eeks) and Arm

















A total of 448 patients w
ere random
ized (intention-to-treat [ITT] population: Arm
 A, n = 150; Arm
 B,  
n = 145; Arm
 C, n = 153)
• 
Patient baseline dem






ith a severe, uncontrolled CRSw
NP setting (Table 1)
• 
82.4%
 had type 2 com







ab vs placebo increased FE
V
1  (L) at W





ab vs placebo reduced A
C
Q
-6 score at W




















































































































, and both treatm
ent groups pooled) vs placebo.
***P < 0.0001 for dupilum
ab (pooled treatm
ent groups) vs placebo. P < 0.0001 for dupilum
ab 300 m
g q2w
 and 300 m
g q2w
–q4w
 vs placebo 
at all tim











on TEAE occurring at higher frequency in dupilum
ab-treated vs placebo-treated patients 
w





on TEAE in all treatm
ent groups w
as nasopharyngitis (Table 2)
• 







ever, TEAEs of w
orsening 
of nasal polyps, asthm
a and sinusitis occurred w
ith a higher cum




























erically greater in the patients w




en than those w
ho sw
itched to q4w
 dosing at W
eek 24 (NPS: −
0.53 and −
0.31 for 300 m
g 
q2w




K-CT scan score: −
1.37 and −









ab reduced the proportion of patients requiring SCS or NP surgery vs placebo: hazard ratio (HR) 
[95%
 CI] 0.238 [0.156–0.364]; nom





 vs placebo reduced the proportion of patients requiring SCS by 74.6%
  
(HR [95%
 CI] 0.254 [0.166–0.391]; nom
inal P < 0.0001) and the proportion of patients requiring NP 
surgery by 89.4%
 (HR [95%
 CI] 0.106 [0.024–0.475]; nom







ab significantly increased FEV
1  and reduced 
ACQ-6 by W
eek 4, w
ith results sustained up to W
eek 24 (P <
 0.0001 vs placebo for both at all tim
e 






ab significantly reduced nasal polyp size (m
easured by NPS) and patient-reported severity of 
nasal congestion (determ
ined by NC score) from
 baseline at W






ab reduced sinus opacification, m
easured by LM
K-CT score, from
 baseline at W
eeks 24 and 
52 (P <






proved HRQoL (assessed by TSS and SNOT-22 score), and also 
significantly im
proved sense of sm
ell (assessed by daily loss-of-sm
ell score and UPSIT score) from
 
baseline at W
eeks 24 and 52 (P <















ith no change in the placebo arm
• 
Dupilum
ab reduced NPS, NC score, and SNOT-22 score w
ith nom
inal significance from
 baseline at 
W
eek 52 (P <
 0.0001 vs placebo for all) (Figure 2A–D and 3C)
W
eek 
LS mean change from BL ±SE
K
aplan–M
eier curve for tim
e to first S
C
S

































 use and/or N
P





ent group here is dupilum
ab treatm
ent Arm
s A+B pooled (first 24 w
eeks only for Arm
 B).
